The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was terminated in April. After sweeping cuts ...

Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...